PacBio: Sub-$300 HiFi Genome Resets Long-Read Sequencing Economics
PacBio began global shipments of its SPRQ-Nx chemistry and multi-use SMRT Cells, cutting list prices for a HiFi long-read human genome to $345 and below $300 at scale. The move lands days before FDA unveiled a draft framework letting gene therapy sponsors reuse prior platform knowledge — tightening the loop between cheaper sequencing and faster genome-edited medicines.
Dr. Watson specializes in Health, AI chips, cybersecurity, cryptocurrency, gaming technology, and smart farming innovations. Technical expert in emerging tech sectors.
LONDON, Friday, June 12, 2026 — PacBio began global shipments of its SPRQ-Nx sequencing chemistry and new multi-use SMRT Cells, dropping the list price of a HiFi long-read human genome to $345 and below $300 at scale. The Menlo Park company said the rollout cuts per-genome costs roughly 30% versus the prior SPRQ chemistry, with the sub-$300 threshold available to Revio customers running about 5,000 genomes a year with applicable discounts. The announcement, made May 26, lands at a moment when AI drug developers are scrambling for richer training data — and when U.S. regulators are quietly making it cheaper to build gene-edited medicines on top of that data.
Key Takeaways
- PacBio's SPRQ-Nx chemistry and multi-use SMRT Cells reduce Revio per-genome costs by about 30%, with list pricing at $345 and sub-$300 at scale.
- Beta testing across 20 sites in Europe, Asia and the U.S., spanning more than 1,400 runs, showed higher yield and lower failure rates.
- DeepConsensus, PacBio's AI consensus algorithm built with Google, was further optimized using Google's AlphaEvolve coding agent.
- The FDA on June 2, 2026 issued draft guidance describing how gene therapy sponsors may leverage public and platform CMC, nonclinical and clinical prior knowledge for products incorporating genome editing of human somatic cells, contingent on product-specific scientific rationale.
- The combination of cheaper long-read sequencing and looser regulatory data requirements is reshaping the cost stack for AI-designed genetic medicines.
Context & Analysis
The sub-$300 long-read genome closes a decade-old pricing gap. PacBio's HiFi reads historically sold at a steep premium to Illumina short-reads because of single-use SMRT Cell consumables. SPRQ-Nx allows the SMRT Cell to be used multiple times, pushing sequencing costs below $300 per human genome at scale. PacBio framed the cost reduction as a 30% drop relative to its previous SPRQ chemistry.
The chemistry release follows a strategic retreat. PacBio closed the sale of its short-read sequencing IP to Illumina on January 30, 2026, receiving $48.1 million in net cash proceeds, with Illumina paying 4% of the net proceeds to Apton's former equity holders to waive remaining milestone obligations, according to GenomeWeb and PacBio's announcement. PacBio said the transaction sharpens its focus on long-read sequencing, accelerates SPRQ-Nx chemistry development, and strengthens the company's balance sheet, according to its Feb. 2, 2026 announcement.
The launch lands inside a broader genomics arms race built around AI training data. PacBio explicitly cited initiatives like the Trillion Gene Atlas as drivers of demand for HiFi sequencing at population scale.
For deeper context, see our related analysis: "Why Genomics Matters in 2026, According to Illumina and Gartner".
Related: Global Genomics Outlook 2026: Enterprise Adoption Accelerates
| Company | Position | Recent Move | Source |
|---|---|---|---|
| PacBio | Long-read leader | SPRQ-Nx shipping; sub-$300 HiFi genome at scale | PacBio press release |
| Illumina | Short-read incumbent | Acquired PacBio short-read IP for $48.1M | GenomeWeb |
| Ultima Genomics | Ultra-high-throughput NGS | UG200 selected for Trillion Gene Atlas | PR Newswire |
| FDA / CBER | Regulator | Draft "Prior Knowledge" guidance for genome-edited gene therapies | FDA |
Competitive Landscape
Illumina remains the dominant short-read vendor, but long-read economics are closing fast. Roche introduced its Axelios sequencing-by-expansion instrument last year, and pricing — not chemistry — has become the central battleground. Leerink Partners analyst Puneet Souda said pricing was the dominant theme at AGBT 2026, as analysts watched whether Roche's Axelios could dent Illumina's clinical NGS lead.
Long-read demand is also being pulled by AI biology. PacBio's collaboration with Basecamp Research is expected to produce approximately 100,000 deeply sequenced samples from over 31 countries across 5 continents, creating what the companies describe as the largest and most diverse high-fidelity metagenomic dataset assembled to date, according to a March 18, 2026 PacBio announcement. Ultima's UG200 is capable of processing more than 60,000 human genomes per year, according to Basecamp Research's Trillion Gene Atlas announcement.
For deeper context, see our Genomics analysis: "Why Biotech Companies Are Accelerating Genomics Adoption in 2026, Led by Illumina, Thermo Fisher and Ginkgo".
Related: Illumina and Thermo Fisher Lead Clinical Genomics Adoption.
| Company | Category | Key Development | Impact |
|---|---|---|---|
| PacBio (Revio) | Long-read HiFi | Sub-$300 genome at scale; multi-use SMRT Cells | Closes economic gap with short-read |
| Illumina | Short-read NGS | Absorbs Onso/Omniome IP from PacBio | Fortifies short-read IP moat |
| Roche | Sequencing-by-expansion (Axelios) | Pricing under scrutiny at AGBT 2026 | Wildcard challenger to Illumina clinical NGS |
| Ultima Genomics | Wafer-based NGS (UG200) | Trillion Gene Atlas anchor partner | Industrial-scale BioAI data generation |
| Element Biosciences | Benchtop short-read (AVITI/VITARI) | $100 genome positioning | Squeezes Illumina at low end |
What It Means
For Enterprise Buyers
Population-scale sequencing programs — biobanks, newborn screening, pharma cohort studies — now have a credible long-read option below the historical $1,000-per-genome psychological line. PacBio is targeting national biobanks, large disease cohorts and AI model-building initiatives that need richer datasets than short-read can produce. Buyers running CRISPR therapeutic pipelines also benefit from a tighter regulatory loop. FDA's new draft guidance lets sponsors lean on public and platform CMC, nonclinical and clinical data for genome-editing submissions, contingent on product-specific scientific rationale, with early INTERACT and pre-IND engagement encouraged.
Additional coverage: Illumina 2026: Distributed WGS MRD Kit Lands Ahead of ASCO
For Investors
PacBio's pivot to a pure-play long-read story has clarified the thesis. The $48.1 million short-read divestment recapitalized the company while sharpening its narrative. The harder question: whether Illumina's clinical NGS franchise can absorb the long-read price compression without ceding market share to PacBio, Ultima, Roche and Element. Pricing — not chemistry — is now the wedge.
Additional coverage: Sequencing Leaders Push Into MENA and India as New Genomics Hubs Emerge.
Related: How Genomics Is Powering Precision Care in 2026, According to Illumina, Thermo Fisher and Gartner
Forward Outlook
Three milestones to watch. First, PacBio plans to extend SPRQ-Nx chemistry to its Vega benchtop system later in 2026, opening the sub-$300 economics to smaller labs. Second, the FDA's draft Prior Knowledge guidance is open for public comment until Sept. 1, 2026, per the Federal Register notice; any final form could shape subsequent IND submissions. Third, Roche's Axelios commercial rollout — with a disclosed $150-per-genome list price and a planned summer 2026 launch, according to GenomeWeb — will help determine whether the clinical NGS market fragments into three tiers or consolidates around Illumina and PacBio.
Related: Bloomberg Intelligence Sees Genomics Reaching $90-120 Billion by 2030.
For deeper context, see our Health Tech analysis: "How Health Tech Is Integrating Data and Care in 2026, According to Gartner and Philips".
For broader market context, see How Genomics Is Powering Precision Care in 2026, According to Illumina, Thermo Fisher and Gartner.
FAQ
See FAQ section below.
Additional reading: Future of AI in Genomics Industry: Top 10 Trends in 2026.
Sources include company disclosures, regulatory filings, analyst reports, and industry briefings.
Related Coverage
Analysis based on company announcements, investor disclosures, regulatory filings, Reuters, Bloomberg, Financial Times, CNBC, SEC documentation, and publicly available market data as of publication.
About the Author
Dr. Emily Watson
AI Platforms, Hardware & Security Analyst
Dr. Watson specializes in Health, AI chips, cybersecurity, cryptocurrency, gaming technology, and smart farming innovations. Technical expert in emerging tech sectors.
Frequently Asked Questions
What did PacBio announce on May 26, 2026?
PacBio announced that its SPRQ-Nx sequencing chemistry and new multi-use SMRT Cells for the Revio HiFi sequencing platform are now shipping worldwide, bringing the per-genome list price to $345 and below $300 at scale for customers sequencing roughly 5,000 genomes per year.
How does PacBio achieve sub-$300 HiFi genomes?
SPRQ-Nx allows the SMRT Cell consumable to be used multiple times, reducing sequencing costs by approximately 30% versus the prior SPRQ chemistry. Combined with DeepConsensus AI improvements developed with Google and optimized using Google's AlphaEvolve coding agent, the workflow generates more usable data per run.
What did the FDA announce on June 2, 2026?
FDA's CBER issued draft guidance titled 'Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing,' allowing sponsors to use publicly available and platform-level CMC, nonclinical and clinical data to support submissions for genome-edited somatic-cell therapies. Public comment is open until September 1, 2026.
Why is this story connected to AI drug discovery?
Cheaper, higher-accuracy long-read sequencing produces richer training data for biological foundation models. PacBio's HiFi technology already underpins large-scale AI training initiatives like Basecamp Research's Trillion Gene Atlas, which plans roughly 100,000 deeply sequenced samples across 31 countries.
How does this affect Illumina's market position?
Illumina remains the dominant short-read NGS vendor and recently acquired PacBio's short-read IP for $48.1 million. But PacBio's sub-$300 long-read economics, alongside competition from Roche's Axelios and Ultima Genomics' UG200, intensifies pricing pressure across the clinical NGS market.